CI vs IMRX · P/E 2.4, rev $274.90B vs $124.2M cap
Cigna Corp (CI) versus Immuneering Corp (IMRX) — a side-by-side from cached financials, not a winner call.
Cigna Corp (CI) is a healthcare plans company listed on US.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
CI currently screens at market cap $71.62B and trailing P/E 2.4. IMRX currently screens at market cap $124.2M.
Not investment advice. Open the CI and IMRX stock pages for the full models.
Not investment advice.